A clinical guide to Cigna's isotretinoin coverage: formulary tier, prior authorization criteria, step therapy requirements, appeal strategies, and real out-of-pocket costs for 2024.
Isotretinoin is not a controlled substance but is prescription-only with mandatory pregnancy-prevention programs like iPLEDGE, PPP, and Healthy Skin worldwide.
A detailed guide to UnitedHealthcare coverage, prior authorization requirements, formulary tier, step therapy, and appeal strategies for isotretinoin (Accutane) in 2024.
Dayvigo (lemborexant) is not approved by the UK's MHRA or EU's EMA as of mid-2024, though it holds FDA and Health Canada approval. See full status details.
Everything you need to know about traveling with GHK-Cu copper tripeptide peptide therapy: how to store vials in transit, manage airport security, maintain your injection schedule across time zones, and protect skin formulations from heat and humidity.
A clinical and coverage guide to liraglutide on Kaiser Permanente plans: formulary tier, prior authorization criteria, step-therapy requirements, appeal pathways, and cost options for 2024.
A guide to vitamin E dosing in NASH (now called MASLD/MASH), covering the PIVENS trial dose, who qualifies, risks of high-dose tocopherol, and where resmetirom fits in the 2024 treatment landscape.
A detailed guide to BCBS Arizona metformin coverage, formulary tiers, prior authorization, cost-saving strategies, and the clinical evidence behind metformin prescribing in 2024.
A guide to Humana's coverage policies, prior authorization requirements, formulary status, and appeal pathways for low-dose naltrexone (LDN) in 2024.
A guide to Humana's coverage rules, prior authorization criteria, formulary tiers, step-therapy requirements, and appeal pathways for oral micronized progesterone (Prometrium).
A guide to AOD-9604's federal and Arizona-specific legal status, compounding pharmacy pathways, prescription requirements, and what patients need to know before seeking access in 2024.
A guide to AOD-9604's legal status in California, covering FDA scheduling, the 503A/503B compounding framework, state pharmacy board rules, and what a compliant prescription pathway looks like in 2024.
A guide to AOD-9604's federal regulatory status, Louisiana-specific pharmacy law, compounding pathways under 503A/503B, and what patients need to do to access the peptide legally in 2024.
A detailed breakdown of AOD-9604's federal and Massachusetts legal status, how the FDA bulk compounding list affects access, and what patients need to know before seeking a prescription in 2024.
A breakdown of BPC-157's federal regulatory status, Alabama pharmacy law, and the only legal access paths available to Alabama residents in 2024.
BPC-157 occupies a legal gray zone in Alabama. Learn what FDA policy, 503A/503B compounding rules, and Alabama pharmacy law actually say about obtaining BPC-157 in 2024.
A guide to BPC-157's federal and Florida legal status, the FDA bulks list, 503A/503B compounding rules, and how to get a legitimate prescription in 2024.
A complete breakdown of BPC-157's legal status in Kentucky, covering FDA scheduling, the 503A/503B compounding framework, the Kentucky Board of Pharmacy rules, and what patients and clinicians need to know before obtaining or prescribing BPC-157 in 2024.
A detailed breakdown of BPC-157's federal and Washington State legal status, including FDA regulatory classification, 503A/503B compounding rules, and what patients and clinicians need to know in 2024.
A guide to the federal and North Carolina legal status of PT-141 (Bremelanotide), how to get a legal prescription, and what compounding rules apply in 2024.
A guide to the federal and Texas-specific legal status of PT-141 (Bremelanotide), how to obtain a lawful prescription, and what compounding rules apply in 2024.
A guide to the federal and Virginia-specific legal status of PT-141 (Bremelanotide), including how to obtain a legal prescription and what compounding rules apply in 2024.
A guide to the federal and California legal framework for Egrifta (tesamorelin): FDA approval status, 503A/503B compounding rules, how to get a valid prescription, and what telehealth patients need to know in 2024.
A complete guide to the federal and Oregon-specific legal status of Egrifta (Tesamorelin), how to get a prescription, and what patients and clinicians need to know in 2024.
A complete guide to the federal and Illinois-specific legal framework for Thymosin Alpha-1, covering FDA status, 503A/503B compounding, prescription pathways, and how to get it legally in 2024.
A guide covering the federal and Texas-specific legal framework for Thymosin Alpha-1, including FDA bulk-drug status, 503A/503B compounding rules, prescription requirements, and how patients can access it legally in 2024.
Understand the regulatory difference between research-only and medical-grade GHK-Cu, how to verify pharmacy quality through HPLC, sterility, and endotoxin testing, and what FDA guidance means for buyers in 2024.
A deep dive into bremelanotide's effects on kidney function, covering pharmacokinetics, renal dosing guidance, clinical trial safety data from RECONNECT, and risk stratification for patients with CKD.
A detailed comparison of how the FDA and EMA view epitalon tetrapeptide, covering approval status, labeling, safety data, and what that means for clinical use in 2024.
Retatrutide trials show weight-loss benefits, not autoimmune treatment. Learn what eligibility rules, arthritis outcomes and safety findings actually mean.
A detailed breakdown of Kaiser Permanente's Saxenda (liraglutide 3 mg) coverage policy, prior authorization criteria, step therapy requirements, appeal steps, and cost-saving alternatives for 2024.
A guide explaining how allergists personalize evaluation, immunotherapy, and pharmacotherapy for patients sensitized to multiple allergens, including Crested Wheatgrass pollen.
A clinician-grade, step-by-step protocol for assessing and managing acne in patients using AndroGel (testosterone topical 1% or 1.62%), from first presentation through escalation and discontinuation criteria.
A clinically specific, week-by-week breakdown of when gynecomastia starts, peaks, and resolves on AndroGel testosterone therapy, with trial data and actionable management at each phase.
A step-by-step protocol for assessing and managing skin irritation caused by AndroGel's alcohol vehicle. Covers grading, first-line fixes, escalation criteria, and when to switch formulations.
A step-by-step, clinician-led approach to weight change on an estradiol patch: distinguish fluid retention from body-composition change, review other causes, and know urgent warning signs.
A clinically specific, step-by-step protocol for assessing and managing tirzepatide-induced nausea, from first dose through escalation and discontinuation decisions.
A clinical deep-dive into how slowing, pausing, stepping down, or microdosing tirzepatide affects pancreatitis risk and resolution, with real protocols and clear escalation criteria.
A clinical week-by-week breakdown of when vomiting starts, peaks, and resolves on Mounjaro (tirzepatide), backed by SURPASS trial data and GLP-1 management guidelines.
A clinical-grade explanation of how semaglutide promotes cholelithiasis and cholecystitis through reduced gallbladder motility and rapid weight loss, with actionable monitoring and management guidance.
No study has tested a diet to lower pancreatitis risk on Ozempic. Here is what the label says about pancreatitis, gallbladder and kidney warnings.
A clinician-grade, step-by-step protocol for assessing and managing acne in patients on testosterone cypionate TRT, from first breakout to escalation and beyond.
A detailed guide to BCBS Arizona Dupixent coverage, prior authorization steps, appeal rights, copay assistance, and what patients can expect to pay in 2024.
A detailed guide to Molina Healthcare Dupixent coverage, prior authorization requirements, step therapy rules, appeals, and cost-assistance programs for dupilumab in 2024.
Dupixent is injected every 2 or 4 weeks based on indication, reflecting its dosing interval. See injection sites, doses, and administration steps.
A guide to Wegovy® (semaglutide 2.4 mg) eligibility: BMI cutoffs, weight-related conditions, contraindications, lab workup, and how telehealth programs like Calibrate fit in.
A guide to Vyleesi (bremelanotide) accelerated titration, covering FDA-approved dosing, RCT evidence from RECONNECT, real-world tolerability data, and a clinical decision framework for adjusting frequency and dose.
A complete clinical guide to restarting and re-titrating Trulicity (dulaglutide) after a break, including FDA-label doses, real-world evidence, and physician decision frameworks.
A plain-English deep dive into the REDUCE-IT trial: the methodology, enrollment criteria, mineral oil controversy, full results tables, and what the 25% MACE reduction means for statin-treated patients with elevated triglycerides today.
Pratley, Aroda, Lingvay et al (Lancet Diabetes Endocrinol 2018;6(4):275-286) is SUSTAIN-7: semaglutide beat dulaglutide on A1C and weight at 40 weeks.
A physician-level breakdown of how vardenafil works: the cGMP/PDE5 signaling cascade, selectivity profile, pharmacokinetics, and what separates it from sildenafil and tadalafil.
A guide covering the average age of menopause onset, perimenopause timelines, early and premature menopause, and what symptoms to expect at each stage.
A clinical guide to endometriosis: what causes it, how it presents, how it is staged, and which medical and surgical treatments have supporting evidence, with a note on what remains uncertain.
Dapagliflozin (Farxiga) first won FDA approval on January 8, 2014 for type 2 diabetes, then expanded to heart failure in 2020 and chronic kidney disease in 2021.
A clinical deep-dive into flibanserin (Addyi) manufacturing, supply chain history, shortage events, mechanism of action, and what prescribers and patients need to know in 2024.
Specific food choices, meal timing, hydration targets, and supplement evidence to reduce nausea on Mounjaro (tirzepatide). Clinically actionable guidance for patients and prescribers managing this side effect in real time.
Specific dietary, hydration, meal-timing, and lifestyle strategies backed by clinical evidence to reduce variable testosterone absorption from AndroGel and stabilize serum levels.
Step-by-step testosterone enanthate self-injection technique with MD-level depth: site selection, needle choice, aspiration debate, dosing schedules, and safety monitoring backed by PubMed and FDA citations.